Ron Philip Buys Shares of Avalo Therapeutics, Inc.
Ron Philip purchased 40,200 shares of Avalo Therapeutics, Inc. on June 23, 2026.
Key Points
- Ron Philip bought 40,200 shares of Avalo Therapeutics, Inc. on June 23, 2026, with shares trading near $18.16 on Friday.
- Avalo Therapeutics, Inc. has a market cap of about $897.8 million, and the stock has a 52-week range of $4.50 to $24.27.
- Analysts have a strong buy consensus with a mean price target of $45.25 for Avalo Therapeutics, Inc.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Ron Philip, an insider at Avalo Therapeutics, Inc. (NasdaqCM: AVTX), purchased 40,200 shares of the company on June 23, 2026. This insider buying activity comes as the stock traded near $18.16 on Friday.
Other Institutional Activity in Avalo Therapeutics, Inc.
FMR LLC significantly increased its position in Avalo by adding 2,659,181 shares, ending with a total of 2,879,481 shares worth about $42.99 million. T. Rowe Price Investment Management, Inc. opened a new position with 2,162,684 shares valued at approximately $32.29 million. Caligan Partners LP boosted its stake by 753,490 shares, bringing its total to 1,635,023 shares valued at $24.41 million. BVF Inc/IL added 277,588 shares, totaling 1,632,845 shares worth $24.38 million. Avoro Capital Advisors LLC also initiated a new position with 1,410,000 shares valued at $21.05 million.
Avalo Therapeutics, Inc. Stock Down 8.1%
Shares of Avalo Therapeutics, Inc. (NasdaqCM: AVTX) traded near $18.16 on Friday. The company has a market capitalization of approximately $897.8 million. Avalo's stock has seen a 52-week low of $4.50 and a high of $24.27, with a 50-day moving average of $15.44 and a 200-day moving average of $15.56. The company has a forward P/E ratio that is not meaningful as it isn't currently profitable, and a beta of 0.819. Its financial health is strong with a current ratio of 7.658 and a quick ratio of 7.069, alongside a debt-to-equity ratio of 0.48.
$AVTX stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Avalo Therapeutics reported revenue of $59,000 with no net margin, reflecting its current stage in development. The company has a negative return on equity of -88.76%. Its next earnings report is expected on August 12, 2026.
Analysts Set New Price Targets
On June 12, 2026, B of A Securities initiated coverage on Avalo Therapeutics with a buy rating and a $35.00 price target. Other analysts, including Citizens and Wedbush, have maintained their buy ratings with price targets ranging from $34.00 to $62.00. The consensus among analysts is a strong buy with a mean price target of $45.25, based on 12 analyst opinions.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a biotechnology company based in Wayne, Pennsylvania. It focuses on developing treatments for immune-mediated inflammatory diseases. Its lead product, AVTX-009, is a monoclonal antibody targeting interleukin-1β, currently in phase 2 clinical trials. The company, led by CEO Dr. Garry A. Neil, employs 33 people and was formerly known as Cerecor Inc. before rebranding in August 2021.
Bottom Line
Insider buying at Avalo Therapeutics by Ron Philip signals potential confidence in the company's future. Institutional investors are also actively adjusting their positions in the company, reflecting varied strategies. Analysts remain bullish on Avalo, with a strong buy consensus and optimistic price targets. Remember, insider and institutional trades are disclosed after the fact and may not indicate the current sentiment.
Get Avalo Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AVTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.